Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of rhoifolin in preparation of drug for preventing and treating osteolytic diseases

A kind of rhodol glycoside and osteolysis technology, which is applied in bone diseases, drug combinations, pharmaceutical formulations, etc., and can solve problems such as prevention and treatment of orthopedic diseases that have not been seen

Inactive Publication Date: 2019-05-17
THE FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Rhodoglutin is a flavonoid compound mainly from Shanxiangyuan or Huajuhong, which also has anti-inflammatory, anti-oxidative and blood pressure-lowering effects, but there are no reports of rhodoglucoside for the prevention and treatment of orthopedic diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of rhoifolin in preparation of drug for preventing and treating osteolytic diseases
  • Application of rhoifolin in preparation of drug for preventing and treating osteolytic diseases
  • Application of rhoifolin in preparation of drug for preventing and treating osteolytic diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0019] 1. Materials and methods

[0020] 1.1 Materials

[0021] Medium: DMEM, a-MEM, and fetal bovine serum (FBS) purchased from Gibco-BRL, USA.

[0022] Reagent: Rhodorin (C27H30O14, molecular weight 578.52) (Chengdu). Antibodies: IkBa, ERK, p-ERK, JNK, p-JNK, p38, p-p38, NFATc1, c-Fos), secondary antibody, b-actin (USA). M-CSF, RANKL (USA). Hydroxyapatite coated culture plate (Beijing), luciferase lysate buffer, DTT solution (USA), titanium particles (USA) and other materials.

[0023] 1.2 Osteoclast differentiation test

[0024] Bone marrow macrophages (BMMs) were harvested from 8-week-old C57BL / 6J mice, and the bone marrow was flushed from the femur and tibia using a small needle. All cells were then cultured overnight in complete α-MEM medium. Then place the BMMs in 8x10 3 The density per well was seeded in 96-well plates and cultured in α-MEM for 24 hours to adhere. For osteoclast differentiation and drug assays, cells were cultured with 100 ng / mL recombinant RAN...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of rhoifolin in preparation of a drug for preventing and treating osteolytic diseases. In-vitro experiments show that the rhoifolin can significantly inhibit theosteoclast formation and bone absorption induced by RANKL and also inhibit the expression of osteoclast-related genes. Western blotting experiments show that the rhoifolin can inhibit NF-[kappa]B andMAPK signaling pathways and two transcription factors of NFATc1 and c-fos; further studies show that the rhoifolin can inhibit P65 from entering nucleus and the activity of NFATc1 and NF-[kappa]B cells. In-vivo experiments show that the rhoifolin can reduce the number of TRAP-positive osteoclasts and bone destruction of skull in a titanium particle-induced skull model. Therefore, the rhoifolin can improve osteolysis induced by osteoclasts, and can become a potential drug for treatment of joint prosthesis loosening, and provides a new treatment option for aseptic loosening of prosthesis.

Description

technical field [0001] The invention belongs to the technical field of bone disease treatment, and in particular relates to the application of rhozoside in the preparation of medicines for the prevention and treatment of osteolytic diseases. Background technique [0002] At present, osteoarthritis, rheumatoid arthritis, bone and joint tuberculosis, septic arthritis, ankylosing spondylitis and other diseases that can cause end-stage bone and joint destruction are increasing year by year, seriously affecting the health and quality of life of patients. Although total joint replacement is a very successful treatment, nearly 30% of total joint replacement patients need revision surgery due to prosthetic loosening and other reasons, which may bring more economic burden to patients and the country. Therefore, it is a great challenge for medical workers to explore the specific mechanism of joint prosthesis loosening and prolong the life of the prosthesis. [0003] At present, it is...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P19/08
Inventor 廖世杰刘云宋方茗冯文宇刘倩赵劲民徐家科丁晓飞马石庭宋慧洁林华豪
Owner THE FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com